Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep 10:46:100455.
doi: 10.1016/j.ahjo.2024.100455. eCollection 2024 Oct.

Achieving equitable access to incretin-based therapies in cardiovascular care

Tina K Reddy  1 , Chloé D Villavaso  2 , Anuhya V Pulapaka  2 , Keith C Ferdinand  2
Affiliations

Achieving equitable access to incretin-based therapies in cardiovascular care

Tina K Reddy et al. Am Heart J Plus. .

Abstract

The role of incretin-based therapies, including glucagon-like peptide-1 receptor agonists (GLP1RAs) and dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonists, in the management of type 2 diabetes mellitus (T2DM) and obesity has been increasingly recognized, along with significant cardiovascular (CV) benefits. Despite the clinical efficacy of incretin-based therapies, high costs, suboptimal access, limited insurance coverage, and therapeutic inertia present substantial barriers to widespread adoption. Overcoming these obstacles is essential for the equitable initiation, access, and utilization of incretin-based therapies. Clinicians must make targeted efforts to ensure health equity in the use of these and other advanced therapies.

Keywords: Cardiovascular disease; Diabetes; Hypertension; Incretin-based therapy; Obesity; Racial/ethnic disparities.

PubMed Disclaimer

Conflict of interest statement

Keith C. Ferdinand is a consultant for Medtronic, Lilly, Amgen, Novartis, Boehringer-Ingelheim TR – None CV – None AP – None

Figures

Fig. 1
Fig. 1
(Central Illustration): 6 Actions to Overcome Disparities in Incretin-Based Treatment.
See this image and copyright information in PMC

References

    1. Emanuel E.J., Dellgren J.L., McCoy M.S., Persad G. Fair allocation of GLP-1 and dual GLP-1-GIP receptor agonists. N. Engl. J. Med. 2024;390(20):1839–1842. doi: 10.1056/NEJMp2400978. - DOI - PubMed
    1. Lavalle Cobo A., Masson W., Lobo M., Barbagelata L., Forte E., Corral P., Nogueira J.P. Ethnic/racial and geographic disparities on major cardiovascular events in glucagon like Peptide-1 receptor agonists trials: a Meta-analysis. Curr. Probl. Cardiol. 2023;48(11) doi: 10.1016/j.cpcardiol.2023.101940. - DOI - PubMed
    1. Larkin H. What to know about PREVENT, the AHA’s new cardiovascular disease risk calculator. JAMA. 2024;331(4):277–279. doi: 10.1001/jama.2023.25115. - DOI - PubMed
    1. Ferdinand K.C. The case for eliminating racial and ethnic cardiovascular disparities in the USA. Nat. Rev. Cardiol. 2024;21(2):65–66. doi: 10.1038/s41569-023-00971-2. - DOI - PubMed
    1. Cromer S.J., Lauffenburger J.C., Levin R., Patorno E. Deficits and disparities in early uptake of glucagon-like peptide 1 receptor agonists and SGLT2i among Medicare-insured adults following a new diagnosis of cardiovascular disease or heart failure. Diabetes Care. 2023;46(1):65–74. doi: 10.2337/dc22-0383. - DOI - PMC - PubMed

LinkOut - more resources